This is a standard post-IPO governance filing with no trading implications. Monitor the company's first earnings release as a public company for fundamental performance data.
Price Chart
Executive Summary
Iambic Therapeutics filed an 8-K on October 16, 2026, reporting the adoption of amended and restated certificate of incorporation and bylaws in connection with the completion of its initial public offering. The filing is a routine post-IPO governance update with no financial data or operational changes.
Key Facts
- Amended and restated certificate of incorporation filed with Delaware Secretary of State on October 16, 2026
- Amended and restated bylaws adopted effective October 16, 2026
- Authorized capital stock: 1,000,000,000 shares of Common Stock ($0.001 par value) and 100,000,000 shares of Preferred Stock ($0.001 par value)
- Board of directors classified into three classes with staggered three-year terms
- Stockholder action by written consent eliminated post-IPO
- Special meetings of stockholders can only be called by Board, CEO, President, or President — stockholders denied this power
- Directors can only be removed for cause by majority vote of stockholders
- 66 2/3% supermajority vote required to amend certain charter provisions
- Exclusive forum provisions for Delaware Chancery Court and federal district court for Securities Act claims
Financial Impact
No financial data reported in this filing
Risk Factors
- No material risks identified in this filing
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-424242 |
| Document: iam-20261016.htm | 0001193125-26-424242 |
| Document: iam-ex3_1.htm | 0001193125-26-424242 |
| Document: 0001193125-26-424242-index-headers.html | 0001193125-26-424242 |
| Document: 0001193125-26-424242-index.html | 0001193125-26-424242 |
| Document: 0001193125-26-424242.txt | 0001193125-26-424242 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Insider Buy | $16.01 $15.80 | ▼ −1.31% | ▼ −1.84% | $14.41 (−9.99%) |
Oct 16, 2026 10d ago | 8-K | $16.34 $16.01 | ▼ −2.02% | ▼ −2.35% | $14.41 (−11.81%) |
Oct 15, 2026 11d ago | 424B4 | $23.81 $16.34 | ▼ −31.37% | ▼ −31.80% | $14.41 (−39.48%) |
Oct 15, 2026 12d ago | EFFECT | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.41 (−23.80%) |
Oct 14, 2026 12d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.41 (−23.80%) |
Oct 14, 2026 12d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.41 (−23.80%) |
Oct 14, 2026 12d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.41 (−23.80%) |
Oct 14, 2026 12d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.41 (−23.80%) |
Oct 14, 2026 12d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.41 (−23.80%) |
Oct 14, 2026 12d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.41 (−23.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers